[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT02586389":3,"trial-entities:NCT02586389":72,"trial-summary:NCT02586389":76},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":21,"primary_purpose":22,"phases":23,"enrollment_info":24,"interventions":27,"primary_outcomes":28,"secondary_outcomes":33,"sex":34,"minimum_age":35,"maximum_age":22,"healthy_volunteers":15,"eligibility_criteria":36,"std_ages":48,"locations":51,"central_contacts":60,"overall_officials":66,"references":70,"see_also_links":71},"NCT02586389","SQNM-CA-101","Specimen Collection from Patients with Non-Hematologic Cancer for Use in Development of a Liquid Biopsy Assay","Collection of Whole Blood and Tissue Specimens from Patients Diagnosed with Non-Hematologic Cancer for Use in Development of a Noninvasive Liquid Biopsy Assay to Determine the Tumor Genomic Profile in Circulating Cell-Free Tumor DNA","RECRUITING","2027-10-31","2024-10","2024-10-16","2015-10-13","Sequenom, Inc.","INDUSTRY",false,"This specimen collection is designed to obtain whole blood and tumor tissue from subjects diagnosed with cancer for the purpose of the development of a noninvasive liquid biopsy assay using next generation sequencing (NGS).","This is a non-significant risk multicenter, longitudinal specimen collection study. At the Baseline Visit, whole blood will be collected to be paired with either a previously collected tumor biopsy tissue sample or a prospectively collected tumor tissue sample. Whole blood samples will also be collected longitudinally at Interim visits for up to 5 years. Interim visits will be on a schedule dictated by their physician's standard-of-care management protocol. No more than 100mL of blood will be collected per month. Tumor tissue from recurrences will be collected for the duration of subject participation (after the Baseline Visit).",[19],"Non-hematologic Cancer",[],"OBSERVATIONAL",null,[],{"count":25,"type":26},3000,"ESTIMATED",[],[29],{"measure":30,"description":31,"timeFrame":32},"biospecimen sample collection for liquid biopsy assay development","Analysis of circulating tumor DNA (ctDNA) in whole blood will be compared to baseline tumor DNA for concordance of mutations related to cancer.","After cancer diagnosis through 5 years of standard of care follow-up visits",[],"ALL","18 Years",{"inclusion":37,"exclusion":42,"raw_text":47},[38,39,40,41],"Subject is 18 years of age or older;","Subject is willing to provide written informed consent;","Subject has a diagnosis of a non-hematologic cancer, has tumor in the body, and has either;","Subject is able, in the professional opinion of the investigator, to provide whole blood at the Baseline Visit and at the Interim Visits.",[43,44,45,46],"Underwent curative-intent surgery for management of the presently diagnosed tumor, at any time prior to the Baseline Visit.","Underwent targeted or non-targeted chemotherapy, hormone receptor blocking therapy, or radiation therapy prior to the Baseline Visit.","Underwent an invasive procedure (biopsy, surgery, thermal ablation) in the 7 days prior to any blood collection (baseline or follow-up).","Any medical or mental condition that would interfere with the subjects' ability to willingly give written informed consent.","Inclusion Criteria:\n\n* Subject is 18 years of age or older;\n* Subject is willing to provide written informed consent;\n* Subject has a diagnosis of a non-hematologic cancer, has tumor in the body, and has either;\n\n  1. residual tumor tissue available for testing by the Sponsor; or\n  2. genomic profiling results from an IVD or LDT assay performed on tumor biopsy tissue; or\n  3. an invasive procedure (biopsy, surgery) scheduled following the Baseline Visit from which residual tumor tissue can be available for testing by the Sponsor.\n* Subject is able, in the professional opinion of the investigator, to provide whole blood at the Baseline Visit and at the Interim Visits.\n\nExclusion Criteria:\n\n* Underwent curative-intent surgery for management of the presently diagnosed tumor, at any time prior to the Baseline Visit.\n* Underwent targeted or non-targeted chemotherapy, hormone receptor blocking therapy, or radiation therapy prior to the Baseline Visit.\n* Underwent an invasive procedure (biopsy, surgery, thermal ablation) in the 7 days prior to any blood collection (baseline or follow-up).\n* Any medical or mental condition that would interfere with the subjects' ability to willingly give written informed consent.",[49,50],"ADULT","OLDER_ADULT",[52],{"facility":53,"status":8,"city":54,"state":55,"country":56,"geoPoint":57},"Idaho Urology","Boise","Idaho","United States",{"lat":58,"lon":59},43.6135,-116.20345,[61],{"name":62,"role":63,"phone":64,"email":65},"Graham McLennan","CONTACT","(858) 202-9162","gmclennan@sequenom.com",[67],{"name":68,"affiliation":13,"role":69},"Sue Beruti, MD","STUDY_DIRECTOR",[],[],{"nct_id":4,"conditions":73,"biomarkers":75},[74],"Solid Neoplasm",[],{"nct_id":4,"found":77,"summary":78,"prompt_version":88},true,{"design":79,"status":80,"heading":81,"summary":82,"follow_up":83,"word_count":84,"commitments":85,"compensation":86,"drugs_mentioned":87},"This is an observational study designed to collect samples from up to 3000 participants. It is a multicenter, longitudinal study, meaning it takes place at multiple locations and follows participants over time.","completed","Specimen Collection for Liquid Biopsy Development in Non-Hematologic Cancer","This study is collecting blood and tumor tissue samples from people with non-hematologic cancer (cancers that don't start in blood-forming tissues like bone marrow or lymph nodes). The goal is to develop a new, less invasive \"liquid biopsy\" test that uses next-generation sequencing (NGS) to detect cancer. You can join if you are 18 or older, have a non-hematologic cancer with tumor in your body, and have either tumor tissue available for testing or previous genomic test results from your tumor. The main goal is to collect these samples from the time of your cancer diagnosis through up to 5 years of follow-up care. The study is currently unclear about its recruitment status.","Participants will be followed for up to 5 years after cancer diagnosis during their standard-of-care follow-up visits.",113,"You would provide whole blood samples at a baseline visit and then periodically for up to 5 years, following your doctor's standard care schedule. Tumor tissue from any cancer recurrences would also be collected.","Not stated in the trial record.",[],"v2"]